A standalone M&A theme involving the acquisition of all shares of スペラファーマ, bringing in contract CMC research and development and manufacturing capabilities for pharmaceuticals and strengthening the contract services platform serving projects from early-stage drug development through regulatory filing. This also includes securing contracts for investigational drugs and testing, as well as the impact on results from fluctuations in manufactured raw-material product lines.